C.U. Correll

538 total citations
17 papers, 377 citations indexed

About

C.U. Correll is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, C.U. Correll has authored 17 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 4 papers in Pharmacology and 3 papers in Clinical Psychology. Recurrent topics in C.U. Correll's work include Schizophrenia research and treatment (6 papers), Treatment of Major Depression (4 papers) and Electroconvulsive Therapy Studies (3 papers). C.U. Correll is often cited by papers focused on Schizophrenia research and treatment (6 papers), Treatment of Major Depression (4 papers) and Electroconvulsive Therapy Studies (3 papers). C.U. Correll collaborates with scholars based in United States, Germany and Belgium. C.U. Correll's co-authors include John M. Kane, Caroline Corves, S. Leucht, Ricardo E. Carrión, Barbara A. Cornblatt, Andrea M. Auther, Danielle McLaughlin, Ruth Olsen, Nicola Veronese and Alexander T. Cohen and has published in prestigious journals such as Psychological Medicine, Schizophrenia Bulletin and Journal of Thrombosis and Haemostasis.

In The Last Decade

C.U. Correll

17 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C.U. Correll United States	5	312	81	77	58	41	17	377
Shubhra Mace United Kingdom	9	277 0.9×	93 1.1×	55 0.7×	125 2.2×	25 0.6×	14	467
Fuminari Misawa Japan	9	431 1.4×	93 1.1×	90 1.2×	93 1.6×	22 0.5×	28	488
Eun Kee Chung South Korea	11	347 1.1×	107 1.3×	88 1.1×	80 1.4×	57 1.4×	15	454
Carrie A. Young United States	6	348 1.1×	54 0.7×	46 0.6×	73 1.3×	31 0.8×	6	392
Corina Young United Kingdom	9	530 1.7×	102 1.3×	154 2.0×	84 1.4×	44 1.1×	11	630
Patricia L. Gilbert United States	3	305 1.0×	101 1.2×	95 1.2×	43 0.7×	11 0.3×	5	352
Michelle C. Sullivan United States	6	281 0.9×	65 0.8×	31 0.4×	33 0.6×	22 0.5×	6	444
Pnina Dorfman-Etrog Israel	8	394 1.3×	124 1.5×	73 0.9×	65 1.1×	15 0.4×	11	521
G Mignot France	3	334 1.1×	108 1.3×	108 1.4×	73 1.3×	14 0.3×	15	414
Mevhibe Tümüklü Türkiye	10	245 0.8×	67 0.8×	57 0.7×	60 1.0×	11 0.3×	13	565

Countries citing papers authored by C.U. Correll

Since Specialization

Citations

This map shows the geographic impact of C.U. Correll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.U. Correll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.U. Correll more than expected).

Fields of papers citing papers by C.U. Correll

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.U. Correll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.U. Correll. The network helps show where C.U. Correll may publish in the future.

Co-authorship network of co-authors of C.U. Correll

This figure shows the co-authorship network connecting the top 25 collaborators of C.U. Correll. A scholar is included among the top collaborators of C.U. Correll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.U. Correll. C.U. Correll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Correll, C.U., et al.. (2022). Efficacy of Risperidone ISM in patients with an acute exacerbation of schizophrenia: a post-hoc analysis on the PANSS-6 score. Neuroscience Applied. 1. 100291–100291. 1 indexed citations

Correll, C.U., et al.. (2022). Safety and efficacy of KarXT (xanomeline–trospium) in patients with schizophrenia – results from a phase 3, randomised, double-blind, placebo-controlled trial (EMERGENT-2). Neuroscience Applied. 1. 100288–100288. 9 indexed citations

Satlin, Andrew, Suresh Durgam, K.E. Vanover, et al.. (2020). P.468 Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study. European Neuropsychopharmacology. 40. S265–S266. 1 indexed citations

Correll, C.U., K.E. Vanover, Suresh Durgam, et al.. (2019). P.673 Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia. European Neuropsychopharmacology. 29. S455–S456. 1 indexed citations

Correll, C.U., Celso Arango, Michael Tocco, et al.. (2017). Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study. European Neuropsychopharmacology. 27. S1099–S1099. 1 indexed citations

Galling, Britta, et al.. (2016). Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: a systematic review, meta-analysis and metaregression analysis. European Neuropsychopharmacology. 26. S459–S459. 1 indexed citations

Veronese, Nicola, Serena Granziera, Marco Solmi, et al.. (2015). Vitamin K antagonists' use and fracture risk: results from a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 13(9). 1665–1675. 33 indexed citations

Carrión, Ricardo E., Danielle McLaughlin, Andrea M. Auther, et al.. (2015). The impact of psychosis on the course of cognition: a prospective, nested case-control study in individuals at clinical high-risk for psychosis. Psychological Medicine. 45(15). 3341–3354. 34 indexed citations

Gerlinger, Gabriel, et al.. (2013). Personal stigma in schizophrenia spectrum disorders: A systematic review of prevalence rates, correlates, impact and interventions, Spanish version. World Psychiatry. 12(2). 147–157. 1 indexed citations

10.

Vancampfort, Davy, Martien Wampers, Alex J. Mitchell, et al.. (2013). A meta-analysis of cardio-metabolic abnormalities in drug naive, first-epidode and multi-episode patients with schizophrenia versus general population controls, Russian version. World Psychiatry. 12(2). 240–250. 1 indexed citations

11.

McEvoy, Joseph P., Leslie Citrome, David Hernández, et al.. (2013). P.3.d.047 Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months. European Neuropsychopharmacology. 23. S486–S486. 1 indexed citations

12.

Correll, C.U., et al.. (2013). Selective Effect s of Individual Antipsychotic Cotreatments on Cardiometabolic and Hormonal Risk Status: Results from a Systematic Review and Meta-analysis. 2 indexed citations

13.

Yu, Wenjing, et al.. (2012). CNR1 and risk of the metabolic syndrome in patients with schizophrenia. Schizophrenia Research. 1 indexed citations

14.

Correll, C.U.. (2012). Utility of second-generation antipsychotics in children and adolescents. Neuropsychiatrie de l Enfance et de l Adolescence. 60(5). S98–S98. 1 indexed citations

15.

Kishimoto, Taishiro, Masahiro Nitta, Michael Borenstein, John M. Kane, & C.U. Correll. (2012). P.3.c.033 Long-acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image and cohort studies. European Neuropsychopharmacology. 22. S335–S336. 4 indexed citations

16.

Correll, C.U., et al.. (2008). Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophrenia Bulletin. 35(2). 443–457. 272 indexed citations

17.

Kane, John M., John H. Krystal, & C.U. Correll. (2003). Treatment Models and Designs for Intervention Research During the Psychotic Prodrome. Schizophrenia Bulletin. 29(4). 747–756. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact